About Celgene Corporation (NASDAQ:CELG)
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CELG
- CUSIP: 15102010
- Web: www.celgene.com
- Market Cap: $94.92 billion
- Outstanding Shares: 782,350,000
- 50 Day Moving Avg: $140.79
- 200 Day Moving Avg: $130.41
- 52 Week Range: $96.93 - $147.17
Sales & Book Value:
- Trailing P/E Ratio: 37.68
- Foreward P/E Ratio: 13.62
- P/E Growth: 0.86
- Annual Revenue: $12.19 billion
- Price / Sales: 7.79
- Book Value: $10.80 per share
- Price / Book: 11.23
- EBITDA: $4.83 billion
- Net Margins: 21.35%
- Return on Equity: 68.51%
- Return on Assets: 17.04%
- Debt-to-Equity Ratio: 1.63%
- Current Ratio: 4.05%
- Quick Ratio: 3.89%
- Average Volume: 4.09 million shs.
- Beta: 1.88
- Short Ratio: 2.63
Frequently Asked Questions for Celgene Corporation (NASDAQ:CELG)
What is Celgene Corporation's stock symbol?
Celgene Corporation trades on the NASDAQ under the ticker symbol "CELG."
When did Celgene Corporation's stock split? How did Celgene Corporation's stock split work?
Celgene Corporation shares split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were payable to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene Corporation stock prior to the split would have 200 shares after the split.
How were Celgene Corporation's earnings last quarter?
Celgene Corporation (NASDAQ:CELG) released its quarterly earnings data on Thursday, July, 27th. The company reported $1.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.61 by $0.21. The company earned $3.27 billion during the quarter, compared to analysts' expectations of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm's revenue for the quarter was up 18.7% compared to the same quarter last year. During the same period last year, the business posted $1.44 earnings per share. View Celgene Corporation's Earnings History.
When will Celgene Corporation make its next earnings announcement?
What guidance has Celgene Corporation issued on next quarter's earnings?
Celgene Corporation updated its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share (EPS) guidance of $7.25-7.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.29. The company issued revenue guidance of $13.0-13.4 billion, compared to the consensus revenue estimate of $13.19 billion.
Where is Celgene Corporation's stock going? Where will Celgene Corporation's stock price be in 2017?
27 equities research analysts have issued 12-month price objectives for Celgene Corporation's stock. Their forecasts range from $98.00 to $175.00. On average, they anticipate Celgene Corporation's share price to reach $150.77 in the next year. View Analyst Ratings for Celgene Corporation.
What are analysts saying about Celgene Corporation stock?
Here are some recent quotes from research analysts about Celgene Corporation stock:
- 1. BTIG Research analysts commented, "After mkt-close on Thursday, Celgene announced termination of the Phase 3 studies (REVOLVE and SUSTAIN) for mongersen in the treatment of Crohn’s disease, and that the Phase 3 DEFINE study will not be initiated. Termination of the programs follow the recommendation of the Data Monitoring Committee (DMC) who indicated futility of mongersen in producing a clinical benefit. Based on the announcement, we have taken our 2023 mongersen estimates to zero from $215m previously, versus consensus at ~$1bn." (10/22/2017)
- 2. According to Zacks Investment Research, "Celgene’s Revlimid continued to outperform driven by further market share increases in newly diagnosed myeloma and the continued increase in treatment duration. Other key products – Pomalyst/Imnovid, Abraxane and Otezla – also performed well. The consecutive increase in annual earnings guidance is also a positive. Celgene continues to progress with its label expansion efforts and pipeline development with sNDA submission for Revlimid in newly diagnosed multiple myeloma targeted for first-quarter 2018. The approval of Idhifa in the U.S. for relapsed and/or refractory acute myeloid leukemia has further boosted the company’s portfolio. Moreover, shares of Celgene have outperformed the industry in the year so far. However, Celgene is highly dependent on Revlimid while foreign exchange headwinds are expected to continue while Abraxane sales are under competitive pressure." (10/18/2017)
- 3. Cann analysts commented, "Celgene announced that Idhifa (enasidenib/AG-221) was granted approval from FDA for the treatment of adult patients with relapsed or refractory AML with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test. It was reported that FDA approval was based on the clinical data from an open-label, single-arm, multicenter, two-cohort clinical trial of adult patients with relapsed or refractory AML with an IDH2 mutation (Study AG221-C-001, NCT01915498). Idhifa was approved concurrently with the Abbott RealTime IDH2 companion diagnostic test, which is FDA-approved as an aid in identifying AML patients for treatment with Idhifa." (8/1/2017)
- 4. Cantor Fitzgerald analysts commented, "Acquisition of worldwide Rights to BeiGene,s (NASDAQ: BGNE, NC) excluding Asia, PD-1 inhibitor for solid tumors, BGB-A317, enhances CELG’s oncology portfolio and augments its immuno-oncology efforts." (7/6/2017)
Who are some of Celgene Corporation's key competitors?
Some companies that are related to Celgene Corporation include Merck & Company (MRK), Amgen (AMGN), Novo Nordisk A/S (NVO), Sanofi (SNY), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Catalent (CTLT), Patheon NV (PTHN) and Taro Pharmaceutical Industries (TARO).
Who are Celgene Corporation's key executives?
Celgene Corporation's management team includes the folowing people:
- Robert J. Hugin, Executive Chairman of the Board
- Scott A. Smith, President, Chief Operating Officer
- Mark J. Alles, Chief Executive Officer, Director
- Peter N. Kellogg, Chief Financial Officer, Executive Vice President
- Terrie Curran, President, Global Inflammation & Immunology Franchise
- Michael F. Pehl, President, Hematology & Oncology
- Rupert J. Vessey, President - Research and Early Development
- Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary
- Michael D. Casey, Lead Independent Director
- Michael W. Bonney, Director
Who owns Celgene Corporation stock?
Celgene Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include Robeco Institutional Asset Management B.V. (0.09%), State Treasurer State of Michigan (0.07%), Douglas Lane & Associates LLC (0.05%), Alta Capital Management LLC (0.05%), APG Asset Management N.V. (0.04%) and Fisher Asset Management LLC (0.03%). Company insiders that own Celgene Corporation stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene Corporation.
Who sold Celgene Corporation stock? Who is selling Celgene Corporation stock?
Celgene Corporation's stock was sold by a variety of institutional investors in the last quarter, including Bridges Investment Counsel Inc., State Treasurer State of Michigan, Alta Capital Management LLC, Douglas Lane & Associates LLC, Oakbrook Investments LLC, Skylands Capital LLC, Robeco Institutional Asset Management B.V. and Edge Wealth Management LLC. Company insiders that have sold Celgene Corporation stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Insider Buying and Selling for Celgene Corporation.
Who bought Celgene Corporation stock? Who is buying Celgene Corporation stock?
Celgene Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Shell Asset Management Co., APG Asset Management N.V., Centre Asset Management LLC, Barometer Capital Management Inc., Rockefeller Financial Services Inc., Mutual of America Capital Management LLC and Meeder Asset Management Inc.. Company insiders that have bought Celgene Corporation stock in the last two years include Corp /De/ Celgene and Michael W Bonney. View Insider Buying and Selling for Celgene Corporation.
How do I buy Celgene Corporation stock?
Shares of Celgene Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celgene Corporation's stock price today?
MarketBeat Community Rating for Celgene Corporation (NASDAQ CELG)MarketBeat's community ratings are surveys of what our community members think about Celgene Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Celgene Corporation stock can currently be purchased for approximately $121.33.
Consensus Ratings for Celgene Corporation (NASDAQ:CELG) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Sell Ratings, 5 Hold Ratings, 20 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.67)|
|Consensus Price Target: ||$150.77 (24.26% upside)|Consensus Price Target History for Celgene Corporation (NASDAQ:CELG)
Analysts' Ratings History for Celgene Corporation (NASDAQ:CELG)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/22/2017||BTIG Research||Reiterated Rating||Hold||N/A|
|10/20/2017||Leerink Swann||Reiterated Rating||Buy||$156.00||N/A|
|10/20/2017||Oppenheimer Holdings, Inc.||Reiterated Rating||Buy||$170.00||N/A|
|10/20/2017||Wells Fargo & Company||Reiterated Rating||Buy||$163.00||N/A|
|10/20/2017||Barclays PLC||Lower Price Target||Equal Weight||$140.00 -> $135.00||N/A|
|10/20/2017||William Blair||Reiterated Rating||Outperform||N/A|
|10/20/2017||Stifel Nicolaus||Lower Price Target||Buy||$155.00 -> $149.00||N/A|
|10/20/2017||Citigroup Inc.||Downgrade||Buy -> Neutral||N/A|
|10/20/2017||Robert W. Baird||Downgrade||Outperform -> Neutral||$162.00 -> $136.00||N/A|
|10/16/2017||J P Morgan Chase & Co||Reiterated Rating||Buy||N/A|
|10/17/2017||Sanford C. Bernstein||Initiated Coverage||Outperform||$162.00||N/A|
|10/17/2017||BMO Capital Markets||Boost Price Target||Positive||$160.00 -> $167.00||N/A|
|10/16/2017||Jefferies Group LLC||Reiterated Rating||Buy||$160.00||N/A|
|10/16/2017||Cantor Fitzgerald||Set Price Target||Buy||$162.00||N/A|
|10/5/2017||Royal Bank Of Canada||Reiterated Rating||Buy||$173.00||N/A|
|10/5/2017||Morgan Stanley||Downgrade||Equal Weight -> Underweight||$120.00||N/A|
|9/15/2017||Mizuho||Boost Price Target||Buy -> Buy||$134.00 -> $158.00||Medium|
|9/13/2017||Bank of America Corporation||Reiterated Rating||Buy||Low|
|9/12/2017||Cowen and Company||Reiterated Rating||Buy||$150.00||Low|
|7/31/2017||Argus||Upgrade||Hold -> Buy||$96.93 -> $160.00||Low|
|7/27/2017||Canaccord Genuity||Set Price Target||Buy||$156.00||Low|
|7/14/2017||SunTrust Banks, Inc.||Reiterated Rating||Buy||$150.00||Low|
|7/6/2017||Credit Suisse Group||Set Price Target||Buy||$148.00||Low|
|5/17/2017||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Sell||$93.00 -> $98.00||Low|
|1/8/2017||Evercore ISI||Reiterated Rating||Buy||$135.00||N/A|
|11/9/2016||Standpoint Research||Downgrade||Buy -> Hold||N/A|
|10/18/2016||Piper Jaffray Companies||Reiterated Rating||Buy||N/A|
|7/6/2016||JMP Securities||Reiterated Rating||Buy||$152.00||N/A|
|4/28/2016||Raymond James Financial, Inc.||Reiterated Rating||Buy||N/A|
|12/18/2015||Atlantic Securities||Initiated Coverage||Neutral -> Neutral||N/A|
Earnings History for Celgene Corporation (NASDAQ:CELG)Earnings History by Quarter for Celgene Corporation (NASDAQ CELG)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/27/2017||6/30/2017||$1.61||$1.82||$3.23 billion||$3.27 billion||View||N/A|
|4/27/2017||Q1 2017||$1.47||$1.68||$3.04 billion||$2.96 billion||View||N/A|
|1/26/2017||Q416||$1.59||$1.61||$3.03 billion||$2.98 billion||View||N/A|
|10/27/2016||Q316||$1.31||$1.58||$2.84 billion||$2.98 billion||View||Listen|
|7/28/2016||Q216||$1.39||$1.44||$2.70 billion||$2.74 billion||View||Listen|
|4/28/2016||Q116||$1.29||$1.32||$2.59 billion||$2.51 billion||View||Listen|
|1/28/2016||Q415||$1.22||$1.18||$2.54 billion||$2.54 billion||View||Listen|
|11/5/2015||Q315||$1.09||$1.23||$2.40 billion||$2.33 billion||View||N/A|
|7/23/2015||Q215||$1.08||$1.23||$2.24 billion||$2.28 billion||View||Listen|
|4/30/2015||Q115||$0.93||$0.95||$2.11 billion||$2.08 billion||View||N/A|
|1/29/2015||Q414||$0.88||$0.91||$2.08 billion||$2.09 billion||View||N/A|
|10/23/2014||Q314||$0.82||$0.97||$1.96 billion||$1.96 billion||View||Listen|
|7/24/2014||Q214||$0.77||$0.80||$1.85 billion||$1.87 billion||View||N/A|
|4/24/2014||Q114||$1.65||$1.67||$1.77 billion||$1.71 billion||View||N/A|
|1/30/2014||Q413||$1.54||$1.51||$1.72 billion||$1.76 billion||View||Listen|
|10/24/2013||Q313||$1.54||$1.56||$1.64 billion||$1.67 billion||View||N/A|
|7/25/2013||Q2 2013||$1.44||$1.52||$1.54 billion||$1.56 billion||View||Listen|
|4/25/2013||Q1 2013||$1.35||$1.37||$1.47 billion||$1.43 billion||View||Listen|
|1/24/2013||Q4 2012||$1.31||$1.32||$1.45 billion||$1.42 billion||View||Listen|
Earnings Estimates for Celgene Corporation (NASDAQ:CELG)
2017 EPS Consensus Estimate: $6.61
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Celgene Corporation (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Celgene Corporation (NASDAQ:CELG)
Insider Ownership Percentage: 0.95%Insider Trades by Quarter for Celgene Corporation (NASDAQ:CELG)
Institutional Ownership Percentage: 79.24%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/25/2017||Terrie Curran||Insider||Sell||1,727||$143.89||$248,498.03|| |
|9/12/2017||Gilla Kaplan||Director||Sell||9,250||$141.56||$1,309,430.00|| |
|9/5/2017||Michael D Casey||Director||Sell||9,250||$139.03||$1,286,027.50|| |
|8/10/2017||Ernest Mario||Director||Sell||18,506||$130.52||$2,415,403.12|| |
|8/2/2017||Gilla Kaplan||Director||Sell||7,500||$134.52||$1,008,900.00|| |
|6/26/2017||James J Loughlin||Director||Sell||18,500||$133.57||$2,471,045.00|| |
|6/22/2017||Michael A Friedman||Director||Sell||10,000||$132.50||$1,325,000.00|| |
|6/22/2017||Robert J Hugin||Insider||Sell||175,970||$134.14||$23,604,615.80|| |
|6/21/2017||Michael D Casey||Director||Sell||9,250||$133.05||$1,230,712.50|| |
|6/19/2017||Michael D. Casey||Director||Sell||9,250||$125.59||$1,161,707.50|| |
|6/15/2017||Rupert Vessey||Insider||Sell||4,785||$120.18||$575,061.30|| |
|5/1/2017||James J Loughlin||Director||Sell||9,250||$124.00||$1,147,000.00|| |
|3/30/2017||Gilla Kaplan||Director||Sell||14,033||$123.83||$1,737,706.39|| |
|3/1/2017||Rupert Vessey||Insider||Sell||4,000||$124.42||$497,680.00|| |
|11/9/2016||Michael A Friedman||Director||Sell||18,600||$116.10||$2,159,460.00|| |
|10/24/2016||Corp /De/ Celgene||Major Shareholder||Buy||800,150||$14.00||$11,202,100.00|| |
|10/3/2016||Michael A Friedman||Director||Sell||56,116||$103.66||$5,816,984.56|| |
|9/23/2016||Richard W Barker||Director||Sell||20,000||$110.82||$2,216,400.00|| |
|9/15/2016||Gilla Kaplan||Director||Sell||9,710||$106.44||$1,033,532.40|| |
|8/23/2016||James J Loughlin||Director||Sell||27,500||$114.10||$3,137,750.00|| |
|8/22/2016||Michael D Casey||Director||Sell||43,134||$114.01||$4,917,707.34|| |
|7/28/2016||Robert J Hugin||Insider||Sell||100,000||$110.00||$11,000,000.00|| |
|6/20/2016||Robert J Hugin||Insider||Sell||75,000||$100.16||$7,512,000.00|| |
|4/4/2016||Gilla Kaplan||Director||Sell||15,967||$101.84||$1,626,079.28|| |
|3/3/2016||Michael W Bonney||Director||Buy||2,000||$103.01||$206,020.00|| |
|2/22/2016||James J Loughlin||Director||Sell||2,100||$104.12||$218,652.00|| |
|12/28/2015||Ernest Mario||Director||Sell||40,000||$119.36||$4,774,400.00|| |
|12/23/2015||Michael D Casey||Director||Sell||20,000||$122.11||$2,442,200.00|| |
|12/21/2015||Gilla Kaplan||Director||Sell||14,464||$110.62||$1,600,007.68|| |
|9/10/2015||Gilla Kaplan||Director||Sell||15,000||$122.45||$1,836,750.00|| |
|9/8/2015||Michael D. Casey||Director||Sell||15,000||$121.76||$1,826,400.00|| |
|7/13/2015||Thomas O Daniel||Insider||Sell||30,156||$120.78||$3,642,241.68|| |
|6/10/2015||Gilla Kaplan||Director||Sell||15,000||$111.74||$1,676,100.00|| |
|6/9/2015||Michael D Casey||Director||Sell||15,000||$111.18||$1,667,700.00|| |
|2/26/2015||Gilla Kaplan||Director||Sell||15,000||$122.89||$1,843,350.00|| |
|2/6/2015||Mark J Alles||Insider||Sell||117,099||$120.68||$14,131,507.32|| |
|1/15/2015||Lawrence V Stein||Insider||Sell||26,666||$120.01||$3,200,186.66|| |
|1/2/2015||Gilla Kaplan||Director||Sell||45,536||$113.47||$5,166,969.92|| |
|12/8/2014||Gilla Kaplan||Director||Sell||15,000||$118.20||$1,773,000.00|| |
|11/3/2014||Robert J Hugin||Insider||Sell||158,000||$106.68||$16,855,440.00|| |
|10/27/2014||Ernest Mario||Director||Sell||100,000||$102.85||$10,285,000.00|| |
|10/24/2014||Michael D Casey||Director||Sell||15,000||$102.94||$1,544,100.00|| |
|9/8/2014||Gilla Kaplan||Director||Sell||30,000||$93.73||$2,811,900.00|| |
|8/4/2014||Perry A Karsen||Insider||Sell||39,104||$87.55||$3,423,555.20|| |
|7/25/2014||Richard W Barker||Director||Sell||17,600||$87.03||$1,531,728.00|| |
|5/1/2014||Perry Karsen||Insider||Sell||11,922||$146.78||$1,749,911.16|| |
|3/4/2014||Michael Casey||Director||Sell||12,770||$162.33||$2,072,954.10|| |
|2/5/2014||Ernest Mario||Director||Sell||13,500||$151.87||$2,050,245.00|| |
|12/23/2013||Lawrence Stein||Insider||Sell||12,062||$168.19||$2,028,707.78|| |
|10/25/2013||Carrie Smith Cox||Director||Sell||18,750||$157.67||$2,956,312.50|| |
|9/4/2013||Gilla Kaplan||Director||Sell||15,000||$143.92||$2,158,800.00|| |
|8/28/2013||Thomas Daniel||Insider||Sell||32,263||$137.06||$4,421,966.78|| |
|8/2/2013||Perry A Karsen||Insider||Sell||93,008||$146.50||$13,625,672.00|| |
|5/30/2013||Robert J Hugin||Insider||Sell||68,087||$123.58||$8,414,191.46|| |
|5/29/2013||Ernest Mario||Director||Buy||1,000||$123.72||$123,720.00|| |
|5/28/2013||Thomas O Daniel||Insider||Sell||32,959||$124.91||$4,116,908.69|| |
Headline Trends for Celgene Corporation (NASDAQ:CELG)
Latest Headlines for Celgene Corporation (NASDAQ:CELG)
Loading headlines, please wait.
Celgene Corporation (CELG) Chart for Sunday, October, 22, 2017